Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/b4/9e/e8/b49ee8c5-8ba5-126b-12d3-4e632ae7b14f/mza_5672426077696131073.jpg/600x600bb.jpg
Last Week in Medicine
Stephen Jenkins, MD, Austin Rupp, MD
62 episodes
4 months ago
Today we do a round-up of some of the recent semaglutide trials. Does semaglutide ever miss? But what about tirzepatide, which causes even more weight loss? We also review two new critical care trials, FLUID and the UK-ROX, new platelet transfusion guidelines, and a new retrospective study of apixaban vs rivaroxaban vs warfarin. Oral Semaglutide for Diabetes with Cardiovascular Disease or CKD (SOUL) Semaglutide for Peripheral Artery Disease (STRIDE) Semaglutide for MASH (ESSENCE) Semagl...
Show more...
Medicine
Health & Fitness,
Alternative Health,
Mental Health
RSS
All content for Last Week in Medicine is the property of Stephen Jenkins, MD, Austin Rupp, MD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Today we do a round-up of some of the recent semaglutide trials. Does semaglutide ever miss? But what about tirzepatide, which causes even more weight loss? We also review two new critical care trials, FLUID and the UK-ROX, new platelet transfusion guidelines, and a new retrospective study of apixaban vs rivaroxaban vs warfarin. Oral Semaglutide for Diabetes with Cardiovascular Disease or CKD (SOUL) Semaglutide for Peripheral Artery Disease (STRIDE) Semaglutide for MASH (ESSENCE) Semagl...
Show more...
Medicine
Health & Fitness,
Alternative Health,
Mental Health
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/b4/9e/e8/b49ee8c5-8ba5-126b-12d3-4e632ae7b14f/mza_5672426077696131073.jpg/600x600bb.jpg
Hydrocortisone for Severe Pneumonia (REMAP-CAP), Intensive BP Control in Diabetes (BPROAD), Aldosterone Synthase Inhibitors for Hypertension (ADVANCE-HTN), Reduced-dose Apixaban for Cancer Associated Thrombosis (API-CAT)
Last Week in Medicine
56 minutes
6 months ago
Hydrocortisone for Severe Pneumonia (REMAP-CAP), Intensive BP Control in Diabetes (BPROAD), Aldosterone Synthase Inhibitors for Hypertension (ADVANCE-HTN), Reduced-dose Apixaban for Cancer Associated Thrombosis (API-CAT)
What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans! We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis. Hydrocortisone for Severe CAP (REMAP-CAP) Predicting Benefit of Corticosteroids in Pneumonia Intens...
Last Week in Medicine
Today we do a round-up of some of the recent semaglutide trials. Does semaglutide ever miss? But what about tirzepatide, which causes even more weight loss? We also review two new critical care trials, FLUID and the UK-ROX, new platelet transfusion guidelines, and a new retrospective study of apixaban vs rivaroxaban vs warfarin. Oral Semaglutide for Diabetes with Cardiovascular Disease or CKD (SOUL) Semaglutide for Peripheral Artery Disease (STRIDE) Semaglutide for MASH (ESSENCE) Semagl...